Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Menu
News
Vicebio
Vicebio Announces $100 Million Series B…
SEPTEMBER 23, 2024
Candid Therapeutics
Candid Therapeutics Debuts with $370M Capital Raise
SEPTEMBER 9, 2024
Beacon Therapeutics
Beacon Therapeutics Raises $170 Million in Series B Funding
JULY 3, 2024
Geron
Geron Announces FDA Approval of Rytelo imetelstat
JUNE 6, 2024
Pheon Therapeutics
Announces $120m Series B financing to fund development of its differentiated ADC pipeline
MAY 21, 2024
Avalo
Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
MARCH 27, 2024
Mineralys Therapeutics
Announces $120 Million Private Placement Financing
FEB 8, 2024
Silence Therapeutics
Announces Oversubscribed $120 Million Private Placement
FEB 5, 2024
Adverum Biotechnologies
Announces $127.5 Million Private Placement Financing
FEB 5, 2024
Astria Therapeutics
Announces Pricing Of $125 Million Underwritten Offering
JAN 30, 2024
CG Oncology
Announces Pricing of Upsized Initial Public Offering
JAN 24, 2024
Edgewise Therapeutics
Announces Pricing of $240 Million Underwritten Offering of Common Stock
JAN 19, 2024
TCGX
TCG Crossover (“TCGX”) Announces Oversubscribed $1B TCGX Fund II
JAN 4, 2024
Gracell Biotechnologies
To be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
DEC 26, 2023
Bristol Myers Squibb
Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
DEC 26, 2023
Icosavax
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
DEC 12, 2023
Carmot Therapeutics
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche
DEC 3, 2023
Vistagen
Vistagen Announces Pricing of $100 Million Underwritten Offering
OCT 2, 2023
Structure Therapeutics
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
SEP 29, 2023
COMPASS Pathways
COMPASS Pathways Announces Up to $285 Million Private Placement Financing
AUG 16, 2023
AN2 Therapeutics
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
AUG 15, 2023
Taysha Gene Therapies
Taysha Gene Therapies Announces $150 Million Private Placement Financing
AUG 14, 2023
ADARx Pharmaceuticals
ADARx Pharmaceuticals Announces Oversubscribed $200 Million Series C Financing
AUG 9, 2023
Gracell Biotechnologies
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing
AUG 7, 2023
Versanis
Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
JULY 13, 2023
Savara
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock
JULY 13, 2023
Upstream Bio
Upstream Bio Announces $200M Series B Financing
JUNE 8, 2023
Alkeus
Alkeus Announces $150 Million Series B Financing
JUNE 5, 2023
Carmot
Carmot Therapeutics Raises $150 Million in Series E
MAY 25, 2023
VectivBio
Ironwood Enters into Definitive Agreement to Acquire VectivBio
MAY 22, 2023
Icosavax
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
MAY 22, 2023
Iveric Bio
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
APRIL 30, 2023
Madrigal
Madrigal Announces Positive Topline Results from the Pivotal Phase 3
DECEMBER 19, 2022
Geron
Geron Announces Positive Top-Line Results from IMerge Phase 3
JANUARY 4, 2023
Abivax
Abivax announces successful oversubscribed EUR 130M cross-over financing
FEBRUARY 22, 2023
Structure Therapeutics
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
FEBRUARY 2, 2023
VectivBio
VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
OCTOBER 13, 2022
Immunovant
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
OCTOBER 4, 2022
Allakos
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
SEPTEMBER 19, 2022
Abivax
Abivax announces successful oversubscribed EUR 49.2M cross-over financing
SEPTEMBER 2, 2022
Upstream Bio
Upstream Bio Launches with $200M Series A
JUNE 2, 2022
Plexium
Plexium Announces $102M Financing
FEBRUARY 23, 2022
Eikon Therapeutics
Eikon Therapeutics Announces $517.8 Million Series B Raise
JANUARY 6, 2022
Arbor Biotechnologies
Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing
NOVEMBER 9, 2021
Entrada Therapeutics
Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering
OCTOBER 28, 2021
ShouTi
ShouTi Secures $100 Million Series B Financing
OCTOBER 20, 2021
Obsidian
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
SEPTEMBER 9, 2021
Artios
Artios Announces $153 Million Series C Financing
JULY 27, 2021
RayzeBio
RayzeBio Secures $108 Million Series C Financing
JUNE 15, 2021
Synthekine
Synthekine Announces $107.5 Million Oversubscribed Series B Financing
JUNE 10, 2021
Affinia Therapeutics
Affinia Therapeutics Closes $110 Million Series B Financing
MAY 3, 2021
TCG X
TCG X Raises Inaugural $824 Million Fund to Advance Disruptive Medicines
APRIL 20, 2021
Entrada Therapeutics
Entrada Therapeutics Announces Closing of $116 Million Series B Financing
MARCH 31, 2021
Aktis Oncology
Aktis Oncology Announces $72 Million Series A Financing to Advance Breakthrough Radiopharmaceuticals
MARCH 18, 2021
Close Menu
Home
About Us
Our Team
Private Portfolio
News
Contact